Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2016, Article ID 2423547, 10 pages
http://dx.doi.org/10.1155/2016/2423547
Review Article

Potential Role of Protein Disulfide Isomerase in Metabolic Syndrome-Derived Platelet Hyperactivity

1Laboratory of Experimental Physiology, Department of Physiological Sciences, Federal University of Maranhão, São Luís, MA, Brazil
2Departamento de Bioquímica and Center for Free Radical and Biomedical Research, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
3Health Sciences Graduate Program, Biological and Health Sciences Center, Federal University of Maranhão, São Luís, MA, Brazil

Received 12 August 2016; Revised 17 October 2016; Accepted 1 November 2016

Academic Editor: Nageswara Madamanchi

Copyright © 2016 Renato Simões Gaspar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. G. Alberti, R. H. Eckel, S. M. Grundy et al., “Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity,” Circulation, vol. 120, pp. 1640–1645, 2009. View at Google Scholar
  2. J. Kaur, “A Comprehensive Review on Metabolic Syndrome,” Cardiology Research and Practice, vol. 2014, Article ID 943162, 21 pages, 2014. View at Publisher · View at Google Scholar
  3. E. S. Ford, W. H. Giles, and W. H. Dietz, “Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey,” The Journal of the American Medical Association, vol. 287, no. 3, pp. 356–359, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Towfighi and B. Ovbiagele, “Metabolic syndrome and stroke,” Current Diabetes Reports, vol. 8, no. 1, pp. 37–41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Kassi, P. Pervanidou, G. Kaltsas, and G. Chrousos, “Metabolic syndrome: definitions and controversies,” BMC Medicine, vol. 9, article 48, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. M.-J. van Rooy, W. Duim, R. Ehlers, A. V. Buys, and E. Pretorius, “Platelet hyperactivity and fibrin clot structure in transient ischemic attack individuals in the presence of metabolic syndrome: a microscopy and thromboelastography® study,” Cardiovascular Diabetology, vol. 14, article 86, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. M.-J. Van Rooy and E. Pretorius, “Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke,” Thrombosis Research, vol. 135, no. 3, pp. 434–442, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Mathew, E. Tay, and K. Cusi, “Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects,” Cardiovascular Diabetology, vol. 9, article 9, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. L. K. Jennings, “Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis,” Thrombosis and Haemostasis, vol. 102, no. 2, pp. 248–257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Santilli, D. Lapenna, S. La Barba, and G. Davì, “Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus,” Free Radical Biology and Medicine, vol. 80, pp. 101–110, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Vizioli, S. Muscari, and A. Muscari, “The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases,” International Journal of Clinical Practice, vol. 63, no. 10, pp. 1509–1515, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Santilli, N. Vazzana, R. Liani, M. T. Guagnano, and G. Davì, “Platelet activation in obesity and metabolic syndrome,” Obesity Reviews, vol. 13, no. 1, pp. 27–42, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. S.-W. Wan, C.-F. Lin, Y.-T. Lu, H.-Y. Lei, R. Anderson, and Y.-S. Lin, “Endothelial cell surface expression of protein disulfide isomerase activates β1 and β3 integrins and facilitates dengue virus infection,” Journal of Cellular Biochemistry, vol. 113, no. 5, pp. 1681–1691, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Chen, Y. Lin, and T. C. Detwiler, “Protein disulfide isomerase activity is released by activated platelets,” Blood, vol. 79, no. 9, pp. 2226–2228, 1992. View at Google Scholar · View at Scopus
  15. C. Wang, W. Li, J. Ren et al., “Structural insights into the redox-regulated dynamic conformations of human protein disulfide isomerase,” Antioxidants & Redox Signaling, vol. 19, no. 1, pp. 36–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Schwaller, B. Wilkinson, and H. F. Gilbert, “Reduction-reoxidation cycles contribute to catalysis of disulfide isomerization by protein-disulfide isomerase,” The Journal of Biological Chemistry, vol. 278, no. 9, pp. 7154–7159, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Cho, D. R. Kennedy, L. Lin et al., “Protein disulfide isomerase capture during thrombus formation in vivo depends on the presence of β3 integrins,” Blood, vol. 120, no. 3, pp. 647–655, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. D. W. Essex, “Redox control of platelet function,” Antioxidants & Redox Signaling, vol. 11, no. 5, pp. 1191–1225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Lahav, E. M. Wijnen, O. Hess et al., “Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin α2β1,” Blood, vol. 102, no. 6, pp. 2085–2092, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. J. K. Burgess, K. A. Hotchkiss, C. Suter et al., “Physical proximity and functional association of glycoprotein 1bα and protein-disulfide isomerase on the platelet plasma membrane,” The Journal of Biological Chemistry, vol. 275, no. 13, pp. 9758–9766, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. D. W. Essex, A. Miller, M. Swiatkowska, and R. D. Feinman, “Protein disulfide isomerase catalyzes the formation of disulfide-linked complexes of vitronectin with thrombin-antithrombin,” Biochemistry, vol. 38, no. 32, pp. 10398–10405, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. K. A. Hotchkiss, C. N. Chesterman, and P. J. Hogg, “Catalysis of disulfide isomerization in thrombospondin 1 by protein disulfide isomerase,” Biochemistry, vol. 35, no. 30, pp. 9761–9767, 1996. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Darley-Usmar and B. Halliwell, “Blood radicals: reactive nitrogen species, reactive oxygen species, transition metal ions, and the vascular system,” Pharmaceutical Research, vol. 13, no. 5, pp. 649–662, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. K. K. Griendling, “NADPH oxidases: new regulators of old functions,” Antioxidants and Redox Signaling, vol. 8, no. 9-10, pp. 1443–1445, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. D. P. Jones, “Redefining oxidative stress,” Antioxidants and Redox Signaling, vol. 8, no. 9-10, pp. 1865–1879, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. C. K. Roberts and K. K. Sindhu, “Oxidative stress and metabolic syndrome,” Life Sciences, vol. 84, no. 21-22, pp. 705–712, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. D. P. Jones and Y.-M. Go, “Redox compartmentalization and cellular stress,” Diabetes, Obesity and Metabolism, vol. 12, supplement 2, pp. 116–125, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. Y.-M. Go and D. P. Jones, “Cysteine/cystine redox signaling in cardiovascular disease,” Free Radical Biology and Medicine, vol. 50, no. 4, pp. 495–509, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Spanidis, A. Mpesios, D. Stagos et al., “Assessment of the redox status in patients with metabolic syndrome and type 2 diabetes reveals great variations,” Experimental and Therapeutic Medicine, vol. 11, no. 3, pp. 895–903, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. L. J. da Fonseca, V. Nunes-Souza, S. Guedes Gda, G. Schettino-Silva, M. A. Mota-Gomes, and L. A. Rabelo, “Oxidative status imbalance in patients with metabolic syndrome: role of the myeloperoxidase/hydrogen peroxide axis,” Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 898501, 14 pages, 2014. View at Publisher · View at Google Scholar
  31. B. Lassègue and K. K. Griendling, “NADPH oxidases: functions and pathologies in the vasculature,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 30, no. 4, pp. 653–661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Lassègue, A. San Martín, and K. K. Griendling, “Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system,” Circulation Research, vol. 110, no. 10, pp. 1364–1390, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. J. D. Lambeth, T. Kawahara, and B. Diebold, “Regulation of Nox and Duox enzymatic activity and expression,” Free Radical Biology and Medicine, vol. 43, no. 3, pp. 319–331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. R. E. Clempus, D. Sorescu, A. E. Dikalova et al., “Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 1, pp. 42–48, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Y. Lee, A. San Martin, P. K. Mehta et al., “Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 4, pp. 480–487, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. K. D. Martyn, L. M. Frederick, K. Von Loehneysen, M. C. Dinauer, and U. G. Knaus, “Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases,” Cellular Signalling, vol. 18, no. 1, pp. 69–82, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. J. D. Van Buul, M. Fernandez-Borja, E. C. Anthony, and P. L. Hordijk, “Expression and localization of NOX2 and NOX4 in primary human endothelial cells,” Antioxidants and Redox Signaling, vol. 7, no. 3-4, pp. 308–317, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. G. R. Drummond and C. G. Sobey, “Endothelial NADPH oxidases: which NOX to target in vascular disease?” Trends in Endocrinology and Metabolism, vol. 25, no. 9, pp. 452–463, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Pignatelli, R. Carnevale, S. Di Santo et al., “Inherited Human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 2, pp. 423–434, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Seno, N. Inoue, D. Gao et al., “Involvement of NADH/NADPH oxidase in human platelet ROS production,” Thrombosis Research, vol. 103, no. 5, pp. 399–409, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Vara, M. Campanella, and G. Pula, “The novel NOX inhibitor 2-acetylphenothiazine impairs collagen-dependent thrombus formation in a GPVI-dependent manner,” British Journal of Pharmacology, vol. 168, no. 1, pp. 212–224, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. M. K. Delaney, K. Kim, B. Estevez et al., “Differential roles of the NADPH-oxidase 1 and 2 in platelet activation and thrombosis,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, no. 5, pp. 846–854, 2016. View at Publisher · View at Google Scholar
  43. C. A. Papaharalambus and K. K. Griendling, “Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury,” Trends in Cardiovascular Medicine, vol. 17, no. 2, pp. 48–54, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Kitada, Z. Zhang, A. Mima, and G. L. King, “Molecular mechanisms of diabetic vascular complications,” Journal of Diabetes Investigation, vol. 1, no. 3, pp. 77–89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Brownlee, “Biochemistry and molecular cell biology of diabetic complications,” Nature, vol. 414, no. 6865, pp. 813–820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. R. P. Robertson, J. Harmon, P. O. T. Tran, and V. Poitout, “β-Cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes,” Diabetes, vol. 53, supplement 1, pp. S119–S124, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. D. C. L. Masquio, A. De Piano, R. M. S. Campos et al., “The role of multicomponent therapy in the metabolic syndrome, inflammation and cardiovascular risk in obese adolescents,” British Journal of Nutrition, vol. 113, no. 12, pp. 1920–1930, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. G. Anfossi, I. Russo, and M. Trovati, “Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome,” Current Vascular Pharmacology, vol. 6, no. 4, pp. 313–328, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Schildknecht, B. van der Loo, K. Weber, K. Tiefenthaler, A. Daiber, and M. M. Bachschmid, “Endogenous peroxynitrite modulates PGHS-1-dependent thromboxane A2 formation and aggregation in human platelets,” Free Radical Biology and Medicine, vol. 45, no. 4, pp. 512–520, 2008. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Patrono, “The Multifaceted clinical readouts of platelet inhibition by low-dose aspirin,” Journal of the American College of Cardiology, vol. 66, no. 1, pp. 74–85, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. L. P. Audoly, B. Rocca, J. E. Fabre et al., “Cardiovascular responses to the isoprostanes iPF(2α)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo,” Circulation, vol. 101, no. 24, pp. 2833–2840, 2000. View at Google Scholar
  52. C. Patrono, A. Falco, and G. Davì, “Isoprostane formation and inhibition in atherothrombosis,” Current Opinion in Pharmacology, vol. 5, no. 2, pp. 198–203, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. G. Davì, M. T. Guagnano, G. Ciabattoni et al., “Platelet activation in obese women: role of inflammation and oxidant stress,” Journal of the American Medical Association, vol. 288, no. 16, pp. 2008–2014, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Magwenzi, C. Woodward, K. S. Wraith et al., “Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade,” Blood, vol. 125, no. 17, pp. 2693–2703, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Trostchansky, V. B. O'Donnell, D. C. Goodwin et al., “Interactions between nitric oxide and peroxynitrite during prostaglandin endoperoxide H synthase-1 catalysis: a free radical mechanism of inactivation,” Free Radical Biology and Medicine, vol. 42, no. 7, pp. 1029–1038, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. N. P. Andrews, M. Husain, N. Dakak, and A. A. Quyyumi, “Platelet inhibitory effect of nitric oxide in the human coronary circulation: impact of endothelial dysfunction,” Journal of the American College of Cardiology, vol. 37, no. 2, pp. 510–516, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. J. C. de Graaf, J. D. Banga, S. Moncada, R. M. J. Palmer, P. G. de Groot, and J. J. Sixma, “Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions,” Circulation, vol. 85, no. 6, pp. 2284–2290, 1992. View at Publisher · View at Google Scholar · View at Scopus
  58. U. Hink, H. Li, H. Mollnau et al., “Mechanisms underlying endothelial dysfunction in diabetes mellitus,” Circulation research, vol. 88, no. 2, pp. E14–E22, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Lerman and A. M. Zeiher, “Endothelial function: cardiac events,” Circulation, vol. 111, no. 3, pp. 363–368, 2005. View at Publisher · View at Google Scholar · View at Scopus
  60. I. Russo, G. Doronzo, L. Mattiello, A. De Salve, M. Trovati, and G. Anfossi, “The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents,” Thrombosis Research, vol. 114, no. 4, pp. 265–273, 2004. View at Publisher · View at Google Scholar · View at Scopus
  61. E. Fuentes and I. Palomo, “Role of oxidative stress on platelet hyperreactivity during aging,” Life Sciences, vol. 148, pp. 17–23, 2016. View at Publisher · View at Google Scholar · View at Scopus
  62. H. W. Kwon, J. H. Shin, H. J. Cho, M. H. Rhee, and H. J. Park, “Total saponin from Korean Red Ginseng inhibits binding of adhesive proteins to glycoprotein IIb/IIIa via phosphorylation of VASP (Ser(157)) and dephosphorylation of PI3K and Akt,” Journal of Ginseng Research, vol. 40, pp. 76–85, 2016. View at Google Scholar
  63. D. Banerjee, S. Mazumder, and A. Kumar Sinha, “Involvement of nitric oxide on calcium mobilization and arachidonic acid pathway activation during platelet aggregation with different aggregating agonists,” International Journal of Biomedical Science, vol. 12, pp. 25–35, 2016. View at Google Scholar
  64. G.-R. Wang, Y. Zhu, P. V. Halushka, T. M. Lincoln, and M. E. Mendelsohn, “Mechanism of platelet inhibition by nitric oxide: In vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 9, pp. 4888–4893, 1998. View at Publisher · View at Google Scholar · View at Scopus
  65. J. E. Freedman, J. Loscalzo, M. R. Barnard, C. Alpert, J. F. Keaney Jr., and A. D. Michelson, “Nitric oxide released from activated platelets inhibits platelet recruitment,” The Journal of Clinical Investigation, vol. 100, no. 2, pp. 350–356, 1997. View at Publisher · View at Google Scholar · View at Scopus
  66. L. A. Blatter and W. G. Wier, “Nitric oxide decreases [Ca2+]i in vascular smooth muscle by inhibition of the calcium current,” Cell Calcium, vol. 15, no. 2, pp. 122–131, 1994. View at Publisher · View at Google Scholar · View at Scopus
  67. P. F. Monteiro, R. P. Morganti, M. A. Delbin et al., “Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production,” Cardiovascular Diabetology, vol. 11, article 5, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. A. S. Brown, M. A. Moro, J. M. Masse, E. M. Cramer, M. Radomski, and V. Darley-Usmar, “Nitric oxide-dependent and independent effects on human platelets treated with peroxynitrite,” Cardiovascular Research, vol. 40, no. 2, pp. 380–388, 1998. View at Publisher · View at Google Scholar · View at Scopus
  69. F. Paneni, J. A. Beckman, M. A. Creager, and F. Cosentino, “Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I,” European Heart Journal, vol. 34, no. 31, pp. 2436–2443, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. T. E. Suslova, A. V. Sitozhevskii, O. N. Ogurkova et al., “Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation,” Frontiers in Physiology, vol. 6, article 501, 2015. View at Publisher · View at Google Scholar · View at Scopus
  71. R. A. Anderson, G. R. Ellis, Y. Y. Chirkov et al., “Determinants of platelet responsiveness to nitric oxide in patients with chronic heart failure,” European Journal of Heart Failure, vol. 6, no. 1, pp. 47–54, 2004. View at Publisher · View at Google Scholar · View at Scopus
  72. A. S. Hajek, J. H. Joist, R. K. Baker, L. Jarett, and W. H. Daughaday, “Demonstration and partial characterization of insulin receptors in human platelets,” The Journal of Clinical Investigation, vol. 63, no. 5, pp. 1060–1065, 1979. View at Publisher · View at Google Scholar · View at Scopus
  73. C. Falcon, G. Pfliegler, H. Deckmyn, and J. Vermylen, “The platelet insulin receptor: detection, partial characterization, and search for a function,” Biochemical and Biophysical Research Communications, vol. 157, no. 3, pp. 1190–1196, 1988. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Trovati, E. M. Mularoni, S. Burzacca et al., “Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients,” Diabetes, vol. 44, no. 11, pp. 1318–1322, 1995. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Udvardy, G. Pfliegler, and K. Rak, “Platelet insulin receptor determination in non-insulin dependent diabetes mellitus,” Experientia, vol. 41, no. 3, pp. 422–423, 1985. View at Publisher · View at Google Scholar · View at Scopus
  76. R. M. Touyz and E. L. Schiffrin, “Blunted inhibition by insulin of agonist-stimulated calcium, ph and aggregatory responses in platelets from hypertensive patients,” Journal of Hypertension, vol. 12, no. 11, pp. 1255–1263, 1994. View at Google Scholar · View at Scopus
  77. M. Trovati, G. Anfossi, F. Cavalot, P. Massucco, E. Mularoni, and G. Emanuelli, “Insulin directly reduces platelet sensitivity to aggregating agents. Studies in vitro and in vivo,” Diabetes, vol. 37, no. 6, pp. 780–786, 1988. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Trovati, G. Anfossi, P. Massucco et al., “Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine- 3',5'-cyclic monophosphate and adenosine-3',5'-cyclic monophosphate,” Diabetes, vol. 46, no. 5, pp. 742–749, 1997. View at Publisher · View at Google Scholar · View at Scopus
  79. A. I. Vinik, T. Erbas, T. Sun Park, R. Nolan, and G. L. Pittenger, “Platelet dysfunction in type 2 diabetes,” Diabetes Care, vol. 24, no. 8, pp. 1476–1485, 2001. View at Publisher · View at Google Scholar · View at Scopus
  80. M. Konieczynska, K. Fil, M. Bazanek, and A. Undas, “Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis,” Thrombosis and Haemostasis, vol. 111, no. 4, pp. 685–693, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Crescente, F. G. Pluthero, L. Li et al., “Intracellular trafficking, localization, and mobilization of platelet-borne thiol isomerases,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 36, no. 6, pp. 1164–1173, 2016. View at Publisher · View at Google Scholar
  82. D. W. Essex, K. Chen, and M. Swiatkowska, “Localization of protein disulfide isomerase to the external surface of the platelet plasma membrane,” Blood, vol. 86, no. 6, pp. 2168–2173, 1995. View at Google Scholar · View at Scopus
  83. J. Zhou, Y. Wu, L. Wang et al., “The C-terminal CGHC motif of protein disulfide isomerase supports thrombosis,” The Journal of Clinical Investigation, vol. 125, no. 12, pp. 4391–4406, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. C. Reinhardt, M.-L. Von Brühl, D. Manukyan et al., “Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation,” Journal of Clinical Investigation, vol. 118, no. 3, pp. 1110–1122, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Holmgren, “Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide,” The Journal of Biological Chemistry, vol. 254, no. 19, pp. 9627–9632, 1979. View at Google Scholar · View at Scopus
  86. G. Tsimerman, A. Roguin, A. Bachar, E. Melamed, B. Brenner, and A. Aharon, “Involvement of microparticles in diabetic vascular complications,” Thrombosis and Haemostasis, vol. 106, no. 2, pp. 310–321, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Raturi, S. Miersch, J. W. Hudson, and B. Mutus, “Platelet microparticle-associated protein disulfide isomerase promotes platelet aggregation and inactivates insulin,” Biochimica et Biophysica Acta (BBA)—Biomembranes, vol. 1778, no. 12, pp. 2790–2796, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Chiu, F. Passam, D. Butera, and P. J. Hogg, “Protein disulfide isomerase in thrombosis,” Seminars in Thrombosis and Hemostasis, vol. 41, no. 7, pp. 765–773, 2015. View at Publisher · View at Google Scholar · View at Scopus
  89. N. Ramachandran, P. Root, X.-M. Jiang, P. J. Hogg, and B. Mutus, “Mechanism of transfer of NO from extracellular S-nitrosothiols into the cytosol by cell-surface protein disulfide isomerase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 17, pp. 9539–9544, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Zai, M. A. Rudd, A. W. Scribner, and J. Loscalzo, “Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide,” Journal of Clinical Investigation, vol. 103, no. 3, pp. 393–399, 1999. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Root, I. Sliskovic, and B. Mutus, “Platelet cell-surface protein disulphide-isomerase mediated S-nitrosoglutathione consumption,” Biochemical Journal, vol. 382, no. 2, pp. 575–580, 2004. View at Publisher · View at Google Scholar · View at Scopus
  92. S. E. Bell, C. M. Shah, and M. P. Gordge, “Protein disulfide-isomerase mediates delivery of nitric oxide redox derivatives into platelets,” Biochemical Journal, vol. 403, no. 2, pp. 283–288, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. T. Uehara, T. Nakamura, D. Yao et al., “S-Nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration,” Nature, vol. 441, no. 7092, pp. 513–517, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. E. J. Heckler, V. Kholodovych, M. Jain, T. Liu, H. Li, and A. Beuve, “Mapping soluble guanylyl cyclase and protein disulfide isomerase regions of interaction,” PLoS ONE, vol. 10, no. 11, Article ID e0143523, 2015. View at Publisher · View at Google Scholar · View at Scopus
  95. E. J. Heckler, P.-A. Crassous, P. Baskaran, and A. Beuve, “Protein disulfide-isomerase interacts with soluble guanylyl cyclase via a redox-based mechanism and modulates its activity,” Biochemical Journal, vol. 452, no. 1, pp. 161–169, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. F. R. M. Laurindo, D. C. Fernandes, A. M. Amanso, L. R. Lopes, and C. X. C. Santos, “Novel role of protein disulfide isomerase in the regulation of NADPH oxidase activity: pathophysiological implications in vascular diseases,” Antioxidants and Redox Signaling, vol. 10, no. 6, pp. 1101–1113, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. D. C. Fernandes, A. H. O. Manoel, J. Wosniak Jr., and F. R. Laurindo, “Protein disulfide isomerase overexpression in vascular smooth muscle cells induces spontaneous preemptive NADPH oxidase activation and Nox1 mRNA expression: effects of nitrosothiol exposure,” Archives of Biochemistry and Biophysics, vol. 484, no. 2, pp. 197–204, 2009. View at Publisher · View at Google Scholar · View at Scopus
  98. L. A. Pescatore, D. Bonatto, F. L. Forti, A. Sadok, H. Kovacic, and F. R. M. Laurindo, “Protein disulfide isomerase is required for platelet-derived growth factor-induced vascular smooth muscle cell migration, Nox1 NADPH oxidase expression, and RhoGTPase activation,” The Journal of Biological Chemistry, vol. 287, no. 35, pp. 29290–29300, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. A. M. A. de Paes, S. Veríssimo-Filho, L. L. Guimarães et al., “Protein disulfide isomerase redoxdependent association with p47phox: evidence for an organizer role in leukocyte NADPH oxidase activation,” Journal of Leukocyte Biology, vol. 90, no. 4, pp. 799–810, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. C. X. C. Santos, B. S. Stolf, P. V. A. Takemoto et al., “Protein disulfide isomerase (PDI) associates with NADPH oxidase and is required for phagocytosis of Leishmania chagasi promastigotes by macrophages,” Journal of Leukocyte Biology, vol. 86, no. 4, pp. 989–998, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Janiszewski, L. R. Lopes, A. O. Carmo et al., “Regulation of NAD(P)H oxidase by associated protein disulfide isomerase in vascular smooth muscle cells,” Journal of Biological Chemistry, vol. 280, no. 49, pp. 40813–40819, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Janiszewski, A. O. Do Carmo, M. A. Pedro, E. Silva, E. Knobel, and F. R. M. Laurindo, “Platelet-derived exosomes of septic individuals possess proapoptotic NAD(P)H oxidase activity: a novel vascular redox pathway,” Critical Care Medicine, vol. 32, no. 3, pp. 818–825, 2004. View at Publisher · View at Google Scholar · View at Scopus
  103. M. H. Gambim, A. de Oliveira do Carmo, L. Marti, S. Veríssimo-Filho, L. R. Lopes, and M. Janiszewski, “Platelet-derived exosomes induce endothelial cell apoptosis through peroxynitrite generation: experimental evidence for a novel mechanism of septic vascular dysfunction,” Critical Care, vol. 11 article R107, 2007. View at Publisher · View at Google Scholar · View at Scopus